Our results reveal that hydroxytyrosol selectively disrupts key oncogenic pathways, including ERBB2/3/4, PI3K-Akt, and MAPK signaling, providing new insights into its anti-melanoma potential and highlighting its utility as a candidate for adjunct therapy in melanoma. Here, ERBB2 is linked to melanoma.